GeneBioTech Co Stock

GeneBioTech Co Equity

The The Equity of GeneBioTech Co (086060.KQ) as of Sep 7, 2026 is 55.00 B KRW. In the previous year, The Equity was 50.97 B KRW — a change of 7.89% (higher).

Equity

55.00 BKRW

YoY

7.89%

Last updated:

In 2026, GeneBioTech Co's equity was 55.00 B KRW, a 7.89% increase from the 50.97 B KRW equity in the previous year.

The GeneBioTech Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
47.96 B KRW
Jan 1, 2019
46.93 B KRW
Jan 1, 2020
45.04 B KRW
Jan 1, 2021
43.95 B KRW
Jan 1, 2022
45.73 B KRW
Jan 1, 2023
48.30 B KRW
Jan 1, 2024
50.97 B KRW
Jan 1, 2025
55.00 B KRW
The GeneBioTech Co Equity history
YEAREquityYoY
55.00 BKRW+7.89%
50.97 BKRW+5.52%
48.30 BKRW+5.64%
45.73 BKRW+4.05%
43.95 BKRW-2.44%
45.04 BKRW-4.02%
46.93 BKRW-2.16%
47.96 BKRW+18.46%
40.49 BKRW+3.76%
39.02 BKRW+35.32%
28.84 BKRW+18.20%
24.40 BKRW—
Access this data via the Eulerpool API
Get Free API Key

GeneBioTech Co Stock analysis

What does GeneBioTech Co do? GeneBioTech Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing GeneBioTech Co's Equity

GeneBioTech Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding GeneBioTech Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating GeneBioTech Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

GeneBioTech Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in GeneBioTech Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about GeneBioTech Co stock

The Equity of GeneBioTech Co is 55.00 B KRW in 2026.

The Equity of GeneBioTech Co changed from 50.97 B KRW to 55.00 B KRW, representing a 7.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity GeneBioTech Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's GeneBioTech Co historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — GeneBioTech Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GeneBioTech Co